0000899243-22-035443.txt : 20221109 0000899243-22-035443.hdr.sgml : 20221109 20221109164050 ACCESSION NUMBER: 0000899243-22-035443 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221107 FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALTSHULER DAVID CENTRAL INDEX KEY: 0001550395 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 221373319 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-07 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001550395 ALTSHULER DAVID C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Global Research and CSO Common Stock 2022-11-07 4 M 0 1303 187.53 A 37380 D Common Stock 2022-11-07 4 S 0 140 299.72 D 37240 D Common Stock 2022-11-07 4 S 0 210 300.96 D 37030 D Common Stock 2022-11-07 4 S 0 189 301.99 D 36841 D Common Stock 2022-11-07 4 S 0 261 303.21 D 36580 D Common Stock 2022-11-07 4 S 0 280 304.58 D 36300 D Common Stock 2022-11-07 4 S 0 140 305.39 D 36160 D Common Stock 2022-11-07 4 S 0 83 306.57 D 36077 D Stock Option (Right to Buy) 187.53 2022-11-07 4 M 0 1303 0.00 D 2029-02-05 Common Stock 1303 1304 D Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $299.72 (range $299.46 to $299.97). Open market sales reported on this line occurred at a weighted average price of $300.96 (range $300.54 to $301.18). Open market sales reported on this line occurred at a weighted average price of $301.99 (range $301.84 to $302.20). Open market sales reported on this line occurred at a weighted average price of $303.21 (range $302.89 to $303.45). Open market sales reported on this line occurred at a weighted average price of $304.58 (range $304.14 to $304.91). Open market sales reported on this line occurred at a weighted average price of $305.39 (range $305.38 to $305.39). Open market sales reported on this line occurred at a weighted average price of $306.57 (range $306.45 to $307.22). The option vests in 16 quarterly installments from 2/6/2019. /s/ Christiana Stevenson, Attorney-in-Fact 2022-11-09